Tel Aviv University

Other

Zilberberg, Alona

Rina Rosin-Arbesfeld

Alona Zilberberg

Ella Sklan

Naama David

Dalia Megiddo

Michal Caspi

Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof.

Methods of inducing read-through of a nonsense mutation associated with ataxia telangiectasia, Rett syndrome or spinal muscular atrophy by erythromycin or azithromycin

The present invention includes methods for treating or preventing a cancer in a mammal comprising administering to the mammal a therapeutically effective amount of a macrolide antibiotic such as tylosin, erythromycin, oleandomycin, spiramycin, and pharmaceutically acceptable salts and derivatives thereof.

Method of treating colorectal cancer that expresses a mutated APC gene by administering erythromycin or tylosin

The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.

MIR-21 promoter driven targeted cancer therapy

Growing community of inventors

Herzliya, Israel

Rina Rosin-Arbesfeld